Drugs / HBM7020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07649265 | Sep 2026 → Nov 2028 expected | Sjogren syndrome, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-08-21 | Harbour BioMed (Guangzhou) Co. Ltd. | Results Harbour BioMed Presented Its Newly Discovered BCMA x CD3 Bispecific Antibody at Cell Engager Summit 2020 harbourbiomed.com ↗
HBM7020 shows potent tumor killing efficacy with limited cytokine release preclinically which suggests its significant therapeutic window |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-23 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Obtains Exclusive License from Harbour BioMed for HBM7020: A Novel BCMAxCD3 Bispecific T-Cell Engager otsuka.co.jp ↗ |
| 2020-08-21 | Harbour BioMed (Guangzhou) Co. Ltd. | Harbour BioMed Presented Its Newly Discovered BCMA x CD3 Bispecific Antibody at Cell Engager Summit 2020 harbourbiomed.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HBM7020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07649265 ↗ |
| Route | Intravenous | “Liquid formulation, administered through intravenous infusion” NCT07649265 ↗ |